Shanghai Net Interest Income from 2010 to 2024

601607 Stock   21.42  0.31  1.43%   
Shanghai Pharmaceuticals' Net Interest Income is decreasing over the years with slightly volatile fluctuation. Net Interest Income is expected to dwindle to about -1.3 B. Net Interest Income is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. View All Fundamentals
 
Net Interest Income  
First Reported
2019-03-31
Previous Quarter
-226.9 M
Current Value
-547.9 M
Quarterly Volatility
97.8 M
 
Covid
Check Shanghai Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Shanghai Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 1.7 B, Selling General Administrative of 16.4 B or Total Revenue of 273.3 B, as well as many indicators such as . Shanghai financial statements analysis is a perfect complement when working with Shanghai Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Shanghai Pharmaceuticals Technical models . Check out the analysis of Shanghai Pharmaceuticals Correlation against competitors.

Currently Active Assets on Macroaxis

Other Information on Investing in Shanghai Stock

Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.